Traumatic brain injury (TBI) is an established risk factor for neurodegenerative disorders and dementias. Epigenetic modifications, such as DNA methylation, may alter the expression of genes without altering the DNA sequence in response to environmental factors. We hypothesized that DNA methylation changes may occur in the injured human brain and be implicated in the neurodegenerative aftermath of TBI. The DNA methylation status of genes related to neurodegeneration; for example, amyloid beta precursor protein (APP), microtubule associated protein tau (MAPT), neurofilament heavy (NEFH), neurofilament medium (NEFM), and neurofilament light (NEFL), was analyzed in fresh, surgically resected human brain tissue from 17 severe TBI patients and compared with brain biopsy samples from 19 patients with idiopathic normal pressure hydrocephalus (iNPH). We also performed an epigenome-wide association study (EWAS) comparing TBI patients with iNPH controls. Thirty-eight CpG sites in the APP, MAPT, NEFH, and NEFL genes were differentially methylated by TBI. Among the top 20 differentially methylated CpG sites, 11 were in the APP gene. In addition, the EWAS evaluating 828,888 CpG sites revealed 308 differentially methylated CpG sites in genes related to cellular/anatomical structure development, cell differentiation, and anatomical morphogenesis. These preliminary findings provide the first evidence of an altered DNA methylome in the injured human brain, and may have implications for the neurodegenerative disorders associated with TBI.
Get full access to this article
View all access options for this article.
References
1.
JohnsonV.E., StewartJ.E., BegbieF.D., TrojanowskiJ.Q., SmithD.H., and StewartW. (2013). Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain, 136, 28–42.
2.
ColeJ.H., JollyA., de SimoniS., BourkeN., PatelM.C., ScottG., and SharpD.J. (2018). Spatial patterns of progressive brain volume loss after moderate–severe traumatic brain injury. Brain, 141, 822–836.
3.
JohnsonV.E., StewartW., and SmithD.H. (2010). Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease?. Nat. Rev. Neurosci. 11, 361–370.
4.
PlassmanB.L., HavlikR.J., SteffensD.C., HelmsM.J., NewmanT.N., DrosdickD., PhillipsC., GauB.A., Welsh–BohmerK.A., BurkeJ.R., GuralnikJ.M., and BreitnerJ.C. (2000). Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology, 55, 1158–1166.
5.
GuoZ., CupplesL.A., KurzA., AuerbachS.H., VolicerL., ChuiH., GreenR.C., SadovnickA.D., DuaraR., DeCarliC., JohnsonK., GoR.C., GrowdonJ.H., HainesJ.L., KukullW.A., and FarrerL.A. (2000). Head injury and the risk of AD in the MIRAGE study. Neurology, 54, 1316–1323.
6.
GardnerR.C., BurkeJ.F., NettiksimmonsJ., GoldmanS., TannerC.M., and YaffeK. (2015). Traumatic brain injury in later life increases risk for Parkinson disease. Ann. Neurol. 77, 987–995.
7.
CraneP.K., GibbonsL.E., Dams-O'ConnorK., TrittschuhE., LeverenzJ.B., KeeneC.D., SonnenJ., MontineT.J., BennettD.A., LeurgansS., SchneiderJ.A., and LarsonE.B. (2016). Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol. 73, 1062–1069.
8.
IkonomovicM.D., UryuK., AbrahamsonE.E., CiallellaJ.R., TrojanowskiJ.Q., LeeV.M., ClarkR.S., MarionD.W., WisniewskiS.R., and DeKoskyS.T. (2004). Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp. Neurol. 190, 192–203.
9.
RobertsG.W., GentlemanS.M., LynchA., MurrayL., LandonM., and GrahamD.I. (1994). Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 57, 419–425.
10.
Abu HamdehS., WaaraE.R., MollerC., SoderbergL., BasunH., AlafuzoffI., HilleredL., LannfeltL., IngelssonM., and MarklundN. (2018). Rapid amyloid-beta oligomer and protofibril accumulation in traumatic brain injury. Brain Pathol. 28, 451–462.
11.
SmithD.H., ChenX.H., IwataA., and GrahamD.I. (2003). Amyloid beta accumulation in axons after traumatic brain injury in humans. J. Neurosurg. 98, 1072–1077.
12.
JohnsonV.E., StewartW., and SmithD.H. (2013). Axonal pathology in traumatic brain injury. Exp. Neurol. 246, 35–43.
13.
MagnoniS., EsparzaT.J., ConteV., CarbonaraM., CarrabbaG., HoltzmanD.M., ZipfelG.J., StocchettiN., and BrodyD.L. (2012). Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain, 135, 1268–1280.
14.
MagnoniS., Mac DonaldC.L., EsparzaT.J., ConteV., SorrellJ., MacriM., BertaniG., BiffiR., CostaA., SammonsB., SnyderA.Z., ShimonyJ.S., TriulziF., StocchettiN., and BrodyD.L. (2015). Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI. Brain, 138, 2263–2277.
15.
NeseliusS., BrisbyH., TheodorssonA., BlennowK., ZetterbergH., and MarcussonJ. (2012). CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PloS One, 7, e33606.
16.
JohnsonV.E., StewartW., and SmithD.H. (2012). Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 22, 142–149.
17.
SmithD.H., HicksR., and PovlishockJ.T. (2013). Therapy development for diffuse axonal injury. J. Neurotrauma, 30, 307–323.
18.
SmithD.H., JohnsonV.E., and StewartW. (2013). Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. Nat. Rev. Neurol. 9, 211–221.
19.
Abu HamdehS., WaaraE.R., MollerC., SoderbergL., BasunH., AlafuzoffI., HilleredL., LannfeltL., IngelssonM., and MarklundN. (2017). Rapid amyloid-beta oligomer and protofibril accumulation in traumatic brain injury. Brain Pathol. (Zurich, Switzerland).
20.
PerrotR., BergesR., BocquetA., and EyerJ. (2008). Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol. Neurobiol. 38, 27–65.
21.
BagnatoS., GrimaldiL.M.E., Di RaimondoG., Sant'AngeloA., BoccagniC., VirgilioV., and AndrioloM. (2017). Prolonged cerebrospinal fluid neurofilament light chain increase in patients with post-traumatic disorders of consciousness. J. Neurotrauma, 34, 2475–2479.
22.
Al NimerF., ThelinE., NystromH., DringA.M., SvenningssonA., PiehlF., NelsonD.W., and BellanderB.M. (2015). Comparative assessment of the prognostic value of biomarkers in traumatic brain injury reveals an independent role for serum levels of neurofilament light. PloS One, 10, e0132177.
23.
WaddingtonC.H. (2012). The epigenotype. 1942. Int. J. Epidemiol. 41, 10–13.
24.
WattF., and MolloyP.L. (1988). Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 2, 1136–1143.
25.
BirdA. (2002). DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21.
26.
Tirado-MagallanesR., RebbaniK., LimR., PradhanS., and BenoukrafT. (2017). Whole genome DNA methylation: beyond genes silencing. Oncotarget, 8, 5629–5637.
27.
MateenB.A., HillC.S., BiddieS.C., and MenonD.K. (2017). DNA methylation: basic biology and application to traumatic brain injury. J. Neurotrauma, 34, 2379–2388.
28.
ElfK., NilssonP., and EnbladP. (2002). Outcome after traumatic brain injury improved by an organized secondary insult program and standardized neurointensive care. Crit. Care Med. 30, 2129–2134.
29.
ElobeidA., LaurellK., CesariniK.G., and AlafuzoffI. (2015). Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. J. Neuropathol. Exp. Neurol. 74, 470–479.
30.
HousemanE.A., AccomandoW.P., KoestlerD.C., ChristensenB.C., MarsitC.J., NelsonH.H., WienckeJ.K., and KelseyK.T. (2012). DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics, 13, 86.
31.
FortinJ.-P., TricheT.J.Jr., and HansenK.D. (2017). Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics, 33, 558–560.
32.
DuP., ZhangX., HuangC.-C., JafariN., KibbeW.A., HouL., and LinS.M. (2010). Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics, 11, 1–9.
33.
JungM., and PfeiferG.P. (2015). Aging and DNA methylation. BMC Biology, 13, 7.
34.
KamburovA., PentchevK., GalickaH., WierlingC., LehrachH., and HerwigR. (2011). ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res. 39, D712–717.
35.
VireE., BrennerC., DeplusR., BlanchonL., FragaM., DidelotC., MoreyL., Van EyndeA., BernardD., VanderwindenJ.M., BollenM., EstellerM., Di CroceL., de LaunoitY., and FuksF. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 439, 871–874.
36.
KaruppagounderS.S., KumarA., ShaoD.S., ZilleM., BourassaM.W., CaulfieldJ.T., AlimI., and RatanR.R. (2015). Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases. Brain Res. 1628, 273–287.
37.
JonesM.J., MooreS.R., and KoborM.S. (2018). Principles and challenges of applying epigenetic epidemiology to psychology. Annu. Rev. Psychol. 69, 459–485.
38.
BlennowK., HardyJ., and ZetterbergH. (2012). The neuropathology and neurobiology of traumatic brain injury. Neuron, 76, 886–899.
39.
ScheltensP., BlennowK., BretelerM.M., de StrooperB., FrisoniG.B., SallowayS., and Van der FlierW.M. (2016). Alzheimer's disease. Lancet, 388, 505–517.
40.
IwataA., NagataK., HatsutaH., TakumaH., BundoM., IwamotoK., TamaokaA., MurayamaS., SaidoT., and TsujiS. (2014). Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Hum. Mol. Genet. 23, 648–656.
41.
MarklundN., BlennowK., ZetterbergH., Ronne-EngstromE., EnbladP., and HilleredL. (2009). Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J. Neurosurg. 110, 1227–1237.
Abu HamdehS., ShevchenkoG., MiJ., MusunuriS., BergquistJ., and MarklundN. (2018). Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue. Sci. Rep. 8, 6807.
44.
McKeeA.C., SternR.A., NowinskiC.J., SteinT.D., AlvarezV.E., DaneshvarD.H., LeeH.S., WojtowiczS.M., HallG., BaughC.M., RileyD.O., KubilusC.A., CormierK.A., JacobsM.A., MartinB.R., AbrahamC.R., IkezuT., ReichardR.R., WolozinB.L., BudsonA.E., GoldsteinL.E., KowallN.W., and CantuR.C. (2013). The spectrum of disease in chronic traumatic encephalopathy. Brain, 136, 43–64.
45.
GasparoniG., BultmannS., LutsikP., KrausT.F.J., SordonS., VlcekJ., DietingerV., SteinmaurerM., HaiderM., MulhollandC.B., ArzbergerT., RoeberS., RiemenschneiderM., KretzschmarH.A., GieseA., LeonhardtH., and WalterJ. (2018). DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex. Epigenetics Chromatin, 11, 41.
46.
HuinV., DeramecourtV., Caparros-LefebvreD., MaurageC.A., DuyckaertsC., KovariE., PasquierF., Buee-ScherrerV., LabreucheJ., BehalH., BueeL., DhaenensC.M., and SablonniereB. (2016). The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Mov. Disord. 31, 1883–1890.
47.
CouplandK.G., MellickG.D., SilburnP.A., MatherK., ArmstrongN.J., SachdevP.S., BrodatyH., HuangY., HallidayG.M., HalluppM., KimW.S., Dobson-StoneC., and KwokJ.B. (2014). DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov. Disord. 29, 1606–1614.
48.
GaetaniL., BlennowK., CalabresiP., Di FilippoM., ParnettiL. and ZetterbergH. (2019). Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry, 90, 870–881.
49.
ShahimP., GrenM., LimanV., AndreassonU., NorgrenN., TegnerY., MattssonN., AndreasenN., OstM., ZetterbergH., NellgardB., and BlennowK. (2016). Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci. Rep. 6, 36791.
50.
LjungqvistJ., ZetterbergH., MitsisM., BlennowK., and SkoglundT. (2017). Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study. J. Neurotrauma, 34, 1124–1127.
51.
BlankM.C., GrinbergI., AryeeE., LaliberteC., ChizhikovV.V., HenkelmanR.M., and MillenK.J. (2011). Multiple developmental programs are altered by loss of Zic1 and Zic4 to cause Dandy-Walker malformation cerebellar pathogenesis. Development, 138, 1207–1216.
52.
TohyamaJ., KatoM., KawasakiS., HaradaN., KawaraH., MatsuiT., AkasakaN., OhashiT., KobayashiY., and MatsumotoN. (2011). Dandy-Walker malformation associated with heterozygous ZIC1 and ZIC4 deletion: Report of a new patient. Am. J. Med. Genet. A, 155a, 130–133.
53.
NishimuraH., SakagamiH., UezuA., FukunagaK., WatanabeM., and KondoH. (2003). Cloning, characterization and expression of two alternatively splicing isoforms of Ca2+/calmodulin-dependent protein kinase I gamma in the rat brain. J. Neurochem. 85, 1216–1227.
54.
WaymanG.A., LeeY.S., TokumitsuH., SilvaA.J., and SoderlingT.R. (2008). Calmodulin-kinases: modulators of neuronal development and plasticity. Neuron, 59, 914–931.
55.
DengM., WeiL., ZuoX., TianY., XieF., HuP., ZhuC., YuF., MengY., WangH., ZhangF., MaH., YeR., ChengH., DuJ., DongW., ZhouS., WangC., WangY., WangJ., ChenX., SunZ., ZhouN., JiangY., LiuX., LiX., ZhangN., LiuN., GuanY., HanY., HanY., LvX., FuY., YuH., XiC., XieD., ZhaoQ., XieP., WangX., ZhangZ., ShenL., CuiY., YinX., ChengH., LiangB., ZhengX., LeeT.M., ChenG., ZhouF., VeldinkJ.H., RobberechtW., LandersJ.E., AndersenP.M., Al-ChalabiA., ShawC., LiuC., TangB., XiaoS., RobertsonJ., ZhangF., van den BergL.H., SunL., LiuJ., YangS., JuX., WangK., and ZhangX. (2013). Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat. Genet. 45, 697–700.
56.
AnR., XiJ., YangX., YaoX., and XuY. (2015). No evidence of association between polymorphisms in four genes and sporadic amyotrophic lateral sclerosis in Han Chinese. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 245–248.
57.
MukherjeeS., KlausC., Pricop-JeckstadtM., MillerJ.A., and StruebingF.L. (2019). A Microglial signature directing human aging and neurodegeneration-related gene networks. Front. Neurosci. 13, 2.
58.
D'OrsiB., EngelT., PfeifferS., NandiS., KaufmannT., HenshallD.C., and PrehnJ.H. (2016). Bok is not pro-apoptotic but suppresses poly ADP-ribose polymerase-dependent cell death pathways and protects against excitotoxic and seizure-induced neuronal injury. J. Neurosci. 36, 4564–4578.
59.
NealM., and RichardsonJ.R. (2018). Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 432–443.
60.
ZhangZ.Y., ZhangZ., FauserU., and SchluesenerH.J. (2007). Global hypomethylation defines a sub-population of reactive microglia/macrophages in experimental traumatic brain injury. Neurosci. Lett. 429, 1–6.
61.
BurdaJ.E., BernsteinA.M., and SofroniewM.V. (2016). Astrocyte roles in traumatic brain injury. Exp. Neurol. 275 Pt. 3, 305–315.
62.
LinH.C., HsiehH.M., ChenY.H., and HuM.L. (2009). S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology, 30, 622–627.
63.
NicollJ.A., RobertsG.W., and GrahamD.I. (1995). Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med. 1, 135–137.
64.
PisanuC., PapadimaE.M., Del ZompoM., and SquassinaA. (2018). Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: potential involvement of epigenetics. Neurosci. Lett. 669, 24–31.
65.
MarklundN., and HilleredL. (2011). Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?. Br. J. Pharmacol. 164, 1207–1229.
66.
LundstromY., LundstromP., PopovaS.N., LindblomR.P.F., and AlafuzoffI. (2019). Detection of changes in immunohistochemical stains caused by postmortem delay and fixation time. Appl. Immunohistochem. Mol. Morphol. 27, 238–245.
67.
Abu HamdehS., VirhammarJ., SehlinD., AlafuzoffI., CesariniK.G., and MarklundN. (2018). Brain tissue Abeta42 levels are linked to shunt response in idiopathic normal pressure hydrocephalus. J. Neurosurg. 130, 121–129.
68.
RizzardiL.F., HickeyP.F., Rodriguez DiBlasiV., TryggvadottirR., CallahanC.M., IdriziA., HansenK.D., and FeinbergA.P. (2019). Neuronal brain-region-specific DNA methylation and chromatin accessibility are associated with neuropsychiatric trait heritability. Nat. Neurosci. 22, 307–316.
69.
MaasA.I., StocchettiN., and BullockR. (2008). Moderate and severe traumatic brain injury in adults. Lancet Neurol. 7, 728–741.
70.
BirS.C., PatraD.P., MaitiT.K., SunH., GuthikondaB., NotarianniC., and NandaA. (2016). Epidemiology of adult-onset hydrocephalus: institutional experience with 2001 patients. Neurosurg. Focus, 41, E5.
71.
HutchinsonP.J., KoliasA.G., TajsicT., AdeleyeA., AkliluA.T., ApriawanT., BajamalA.H., BarthelemyE.J., DeviB.I., BhatD., BultersD., ChesnutR., CiterioG., CooperD.J., CzosnykaM., EdemI., El-GhandourN.M.F., FigajiA., FountasK.N., GallagherC., HawrylukG.W.J., IaccarinoC., JosephM., KhanT., LaekeT., LevchenkoO., LiuB., LiuW., MaasA., ManleyG.T., MansonP., MazzeoA.T., MenonD.K., MichaelD.B., MuehlschlegelS., OkonkwoD.O., ParkK.B., RosenfeldJ.V., RosseauG., RubianoA.M., ShabaniH.K., StocchettiN., TimmonsS.D., TimofeevI., UffC., UllmanJ.S., ValadkaA., WaranV., WellsA., WilsonM.H., and ServadeiF. (2019). Consensus statement from the International Consensus Meeting on the Role of Decompressive Craniectomy in the Management of Traumatic Brain Injury: Consensus statement. Acta Neurochir. 161, 1261–1274.
72.
PolicicchioS., WasherS., VianaJ., IatrouA., BurrageJ., HannonE., TureckiG., KaminskyZ., MillJ., DempsterE.L., and MurphyT.M. (2020). Genome-wide DNA methylation meta-analysis in the brains of suicide completers. Transl. Psychiatry, 10, 69.
73.
OngM.L., and HolbrookJ.D. (2014). Novel region discovery method for Infinium 450K DNA methylation data reveals changes associated with aging in muscle and neuronal pathways. Aging Cell, 13, 142–155.
74.
MansellG., Gorrie-StoneT.J., BaoY., KumariM., SchalkwykL.S., MillJ., and HannonE. (2019). Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics, 20, 366.
75.
ZhouZ., LunettaK.L., SmithA.K., WolfE.J., StoneA., SchichmanS.A., McGlincheyR.E., MilbergW.P., MillerM.W., and LogueM.W. (2019). Correction for multiple testing in candidate-gene methylation studies. Epigenomics, 11, 1089–1105.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
